GLAXOSMITHKLINE PLC Form 6-K February 06, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 06th February 2019

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

| GlaxoSmithKline plc (the 'Company') | | | |
|-------------------------------------|--|---|--|
| Tra | ansaction notification | | |
| 1. | Details of PDMR/person closely associ | iated with them ('PCA') | |
| a) | Name | Sir Philip Hampton | |
| b) | Position/status | Non-Executive Chairman | |
| c) | Initial notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) | | |
| | each place where transaction(s) has been conducted | | |
| | | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |

a) Description of the financial instrument

| b) Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018. |
|--|---|
| c) Price(s) and volume(s) | Price(s) Volume(s) £14.95 2,926.421 |
| d) Aggregated information Aggregated volume Price | n/a (single transaction) |
| e) Date of the transaction | 2019-02-06 |
| f) Place of the transaction | n/a |

| 1. | Details of PDMR/person closel | y associated with them ('PCA') |
|----|-------------------------------|--------------------------------|
| a) | Name | Mr Vindi Banga |
| | | Sonior Indonandant |

| b) | Position/status | Senior Independent |
|--------------------------|-----------------|------------------------|
| U) | | Non-Executive Director |
| c) Initial notification/ | | Initial notification |
| •) | amendment | |
| 2 | | |

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYL01D793 Details of the transaction(s): section to be repeated for (i) each type
- 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)
- each place where transaction(s) has been conducted Ordinary shares of 25 pence

each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

| b) Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018. |
|--|---|
| c) Price(s) and volume(s) | Price(s) Volume(s) £14.95 480.769 |
| d) Aggregated information Aggregated volume Price | n/a (single transaction) |
| e) Date of the transaction | 2019-02-06 |
| f) Place of the transaction | n/a |

- 1. Details of PDMR/person closely associated with them ('PCA') a) Name Dr Vivienne Cox Independent Non-Executive b) Position/status Director Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

| | | Acquisition | n of notional | |
|---------------|---------------------------------------|---------------------------|------------------------------|--|
| | | Ordinary Shares under the | | |
| | | share alloc | ation arrangements | |
| | Nature of the transaction | for Indepen | ndent | |
| b) Nature | | Non-Execu | ative Directors for | |
| | | the period | the period of service from 1 | |
| | | October 20 |)18 to 31 | |
| | | December | 2018. | |
| | | | | |
| c) $Price(s)$ | and volume(s) | Price(s) | Volume(s) | |
| | Theo(b) and vorame(b) | £14.95 | 355.351 | |
| a) | ated information ated volume Price | n/a (single | transaction) | |
| e) Date of | the transaction | 2019-02-0 | 6 | |
| f) Place of | Place of the transaction | n/a | | |

1. Details of PDMR/person closely associated with them ('PCA')

| Name | Ms Lynn Elsenhans |
|--|---|
| Position/status | Independent Non-Executive Director |
| Initial notification/ amendment | Initial notification |
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| Name | GlaxoSmithKline plc |
| LEI | 5493000HZTVUYLO1D793 |
| Details of the transaction(s): section to be repeated for (i) each type | |
| . of instrument; (ii) each type of transaction; (iii) each date; and (iv) | |
| each place where transaction(s) has been | en conducted |
| Description of the financial instrument | American Depositary Shares |
| | Position/status Initial notification/ amendment Details of the issuer, emission allowand platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to of instrument; (ii) each type of transact each place where transaction(s) has been |

('ADSs') ISIN: US37733W1053

| b) | Nature of the transaction | under the sh arrangemen Non-Execut | |
|----|---|--|------------------------|
| c) | Price(s) and volume(s) | Price(s) \$39.27 | Volume(s) 1,049.907 |
| d) | Aggregated information Aggregated volume Price | n/a (single t | ransaction) |
| e) | Date of the transaction | 2019-02-06 | |
| f) | Place of the transaction | n/a | |

1. Details of PDMR/person closely associated with them ('PCA')

| a) | Name | Dr Laurie Glimcher | |
|------------|---|----------------------------------|--|
| b) | Position/status | Independent Non-Executive | |
| 0) | | Director | |
| 2) | Initial notification/ | Initial matification | |
| c) | amendment | Initial notification | |
| 2. | Details of the issuer, emission allowand | e market participant, auction | |
| Ζ. | platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| | Details of the transaction(s): section to | be repeated for (i) each type of | |
| 3. | instrument; (ii) each type of transaction; (iii) each date; and (iv) each | | |
| | place where transaction(s) has been conducted | | |
| | | American Depositary Shares | |
| | | ('ADSs') | |
| | | ISIN: US37733W1053 | |

- a) Description of the financial instrument
- b) Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

ISIN: US37733W1053

Acquisition of notional ADSs

| α | Price(s) and volume(s) | Price(s) | Volume(s) |
|----------|---|---------------|-------------|
| C) | Filee(s) and volume(s) | \$39.27 | 1,399.876 |
| d) | Aggregated information Aggregated volume Price | n/a (single t | ransaction) |
| | Date of the transaction | 2019-02-06 | |
| 0) | | 2017-02-00 | |
| f) | Place of the transaction | n/a | |

| 1. | . Details of PDMR/person closely associated with them ('PCA') | | |
|----|--|------------------------------------|--|
| a) | Name | Dr Jesse Goodman | |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| | Details of the transaction(s): section to be repeated for (i) each type | | |
| 3. | . of instrument; (ii) each type of transaction; (iii) each date; and (iv) | | |
| | each place where transaction(s) has been conducted | | |
| | - | American Depositary Shares | |
| | | ('ADSs') | |
| | | | |

a) Description of the financial instrument

| b) Nature of the transaction | under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018. |
|--|---|
| c) Price(s) and volume(s) | Price(s) Volume(s) \$39.27 422.376 |
| d) Aggregated information Aggregated volume Price | n/a (single transaction) |
| e) Date of the transaction | 2019-02-06 |
| f) Place of the transaction | n/a |

- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name
 b) Position/status
 b) Position/status
 b) Ms Judy Lewent
 c) Independent Non-Executive
 c) Director
- c) Initial notification/ amendment Initial notification
- 2. Details of the issuer, emission allowance market participant, auction
- ². platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type
 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares ('ADSs') ISIN: US37733W1053

a) Description of the financial instrument

| b) | Nature of the transaction | under the sl arrangemer Non-Execu | | |
|----|--|---|----------------------|--|
| c) | Price(s) and volume(s) | Price(s) \$39.27 | Volume(s) 470.648 | |
| d) | Aggregated information Aggregated volume Price n/a (sin | | le transaction) | |
| e) | Date of the transaction | 2019-02-06 | | |
| f) | Place of the transaction | n/a | | |

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

- Mr Urs Rohner
- b) Position/status
 c) Initial notification/
 Independent Non-Executive Director
 Initial notification

amendment

- 2. Details of the issuer, emission allowance market participant, auction
- ². platform, auctioneer or auction monitor
- a) Name

- GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type
- 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence

each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

| | | Acquisition of notional | | |
|----|--|--|-----------|-----|
| | | Ordinary Shares under the | | |
| | | share allocation arrangements | | |
| | Nature of the transaction | for Independent | | |
| b) | | Non-Executive Directors for | | |
| | | the period of service from 1 | | |
| | | October 2018 to 31 | | |
| | | December 2018. | | |
| | | | | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| | | £14.95 | 480.769 | |
| d) | Aggregated information Aggregated volumePrice | n/a (single transaction) 2019-02-06 | | |
| | | | | e) |
| f) | Place of the transaction | | | n/a |
| | | | | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc (Registrant)

Date: February 06th, 2019

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc